A Phase Ⅰ/Ⅰb Study to Investigate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of Toripalimab (Anti-PD-1 Antibody) in Combination With Senaparib (PARP Inhibitor) in Patients With Advanced Solid Tumors

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I

Latest Information Update: 21 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Senaparib (Primary) ; Toripalimab (Primary)
Indications Adenocarcinoma; Advanced breast cancer; Bladder cancer; Endometrial cancer; HER2 negative breast cancer; Nasopharyngeal cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Pelvic cancer; Prostate cancer; Small cell lung cancer; Solid tumours; Squamous cell cancer; Ureteral neoplasms; Urethral cancer; Urogenital cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Shanghai Junshi Biosciences

Most Recent Events

18 Sep 2022 Status changed from not yet recruiting to withdrawn prior to enrolment.
08 Mar 2022 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight